Is BPC-157 the same thing as Thymosin Beta-4?

No, they are completely different molecules. BPC-157 is a 15-amino-acid peptide derived from gastric juice research, focused mainly on tissue and gut healing in animal models.[1] Thymosin Beta-4 is a naturally occurring protein fragment linked to cell migration and immune function. They have been combined in some small pilot studies, but they work through different biological pathways.

Have either of these peptides been tested in humans?

Only in very small, early-stage studies. BPC-157 has been examined in a few pilot trials, including one retrospective study of twelve patients with chronic knee pain.[3] Thymosin Beta-4 has similarly limited human data. Neither has completed large, rigorous clinical trials, so both are considered investigational compounds, not approved treatments.[4]

Why do research doses look so different between studies?

Most studies are done in rodents, and doses are calculated by body weight — typically micrograms per kilogram. Species, injury type, route of administration (injection vs. oral), and study duration all change the numbers significantly.[2] This makes direct comparison tricky. Our research calculator can help you see how weight-based doses from published papers scale across different body weights for educational purposes.

Is BPC-157 banned in sports?

It was temporarily flagged by the World Anti-Doping Agency in 2022, but as of the most recent review it is not listed as a banned substance by WADA.[1] However, regulations change, and individual sports organizations may have their own rules. A 2025 systematic review recommends athletes check their specific organization's guidelines before considering any peptide.[3]

BPC-157 vs Thymosin Beta-4: Research Dosing Compared

Two Peptides, Two Very Different Stories

Walk into any peptide research forum and you'll see two names come up constantly: BPC-157 and Thymosin Beta-4. They're often lumped together — sometimes even injected together in pilot studies — but they are fundamentally different molecules with different research histories. Let's untangle them.

What Is BPC-157?

BPC stands for Body Protection Compound. It's a chain of exactly 15 amino acids (the building blocks of proteins), originally isolated from human gastric — that means stomach — juice.^[1] Researchers became interested in it because the stomach lining has a remarkable ability to repair itself, and they wanted to know why.

Preclinical studies (meaning studies in animals, not yet in people) consistently show BPC-157 speeding up healing in tendons, ligaments, and muscle tissue.^[2] More recent systematic reviews confirm it influences growth hormone receptors, promotes the growth of new blood vessels (called angiogenesis), and dials down inflammatory signals.^[3] In plain terms: in animal models, it nudges damaged tissue toward repair mode.

One small retrospective human study injected BPC-157 directly into the knee joint for chronic pain. Seven out of twelve patients reported relief lasting more than six months.^[3] That's interesting — but twelve patients is a very small group, so researchers are cautious.^[4]

BPC-157 is not FDA-approved and is considered investigational. It was briefly flagged by the World Anti-Doping Agency in 2022 but is not currently on their banned list.^[1]

What Is Thymosin Beta-4?

Thymosin Beta-4 (often abbreviated TB-4) is a small protein fragment found naturally throughout the human body — in blood platelets, white blood cells, and most tissues. It plays a key role in cell migration (helping cells move to where they're needed) and in controlling the early stages of inflammation. Think of it as a molecular traffic controller that tells repair cells where to go after an injury.

Unlike BPC-157, which was discovered through gastric research, TB-4 emerged from immunology — the science of immune function. Early research explored it for wound healing, heart tissue protection, and corneal (eye surface) repair. Some pilot work has combined it with BPC-157; one small retrospective study looked at intra-articular injections of BPC-157 alone or paired with TB-4 for knee pain.^[5] Separating the effects of each compound in combined studies is tricky, which is why researchers prefer studying them individually.

How Research Dosing Differs

This is where things get practical for anyone trying to read the literature intelligently. Animal studies use weight-based dosing, and the numbers vary quite a bit between the two peptides.

BPC-157 animal studies commonly use doses in the range of 1–10 micrograms per kilogram of body weight, administered by injection or sometimes orally.^[2] Its half-life — how long it stays active — is under 30 minutes in the bloodstream.^[3]
Thymosin Beta-4 animal studies tend to use higher microgram-to-milligram ranges, often applied locally to wound sites or injected systemically, depending on the tissue being studied.
Neither compound has an established, validated human dosing protocol. Any numbers you see outside a controlled study are extrapolations — educated guesses, not confirmed clinical doses.
BPC-157 can be given as a subcutaneous injection (under the skin), intramuscularly, or even orally in some animal models — a flexibility that has attracted researcher interest.^[6]

Use our calculator to explore how weight-based research doses from published studies translate across different body weights — purely for understanding the literature, not for personal use.

Quick Comparison: BPC-157 vs Thymosin Beta-4

Origin: BPC-157 → stomach lining; TB-4 → immune/blood system
Primary research focus: BPC-157 → tendon, ligament, gut healing^[2]; TB-4 → wound healing, inflammation, cardiac repair
Human trial data: Both extremely limited — BPC-157 has a handful of small pilot studies^[4]; TB-4 similarly sparse
Dosing route in studies: BPC-157 → injection or oral; TB-4 → mainly injection or topical
Regulatory status: Both unapproved for human medical use by the FDA
Safety data: Animal models show few adverse effects for BPC-157^[3]; human clinical safety data is missing for both

How to Choose What to Read About

Your starting point should be your area of curiosity. Interested in soft tissue and gut research? The BPC-157 literature is larger and more systematically reviewed.^[3] Interested in immune modulation or cardiac tissue? The Thymosin Beta-4 literature is your better entry point.

Either way, look for peer-reviewed animal studies first, note the species and dose, and treat any human anecdotes you find online with healthy skepticism. The research community itself calls for well-designed clinical trials before either compound moves toward real medical use.^[4]

Bottom line: both peptides are genuinely fascinating areas of early-stage science. Neither is ready for clinical prescription. Read widely, cite carefully, and always check whether a study was done in rats or in people — it matters enormously.

Sources

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. — Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999.
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. — Cell and tissue research, 2019. PMID 30915550.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. — HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949.
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. — Current reviews in musculoskeletal medicine, 2025. PMID 40789979.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. — Alternative therapies in health and medicine, 2021. PMID 34324435.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. — Frontiers in pharmacology, 2021. PMID 34267654.

BPC-157 vs Thymosin Beta-4: A Simple Research Comparison